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Introduction
BRCA1 is a well-established tumor suppressor, and women 
carrying germline mutations in BRCA1 have a high risk of 
developing breast and ovarian cancer (Neuhausen and Marshall, 
1994; Wooster and Weber, 2003). Tumors that arise often lack 
expression of estrogen and progesterone receptors and Her2, 
being classified as triple-negative breast cancers (TNBC; 
Turner and Reis-Filho, 2006). BRCA1 participates in DNA 
double-strand break (DSB) repair, S and G2/M phase cell- 
cycle checkpoints after damage, control of centrosome numbers, 
maintenance of heterochromatin, and transcriptional regulation 
of several genes (Scully and Livingston, 2000; Mullan et al., 
2006; Zhu et al., 2011). In addition, BRCA1 function is linked 
to epigenetic mechanisms such as DNA methylation and miRNA 
biogenesis (Shukla et al., 2010; Kawai and Amano, 2012; Tanic 
et al., 2012).
Recruitment of BRCA1 to DNA DSBs facilitates repair 
by homologous recombination (HR), and loss of BRCA1 results 
in genomic instability characterized by unrepaired DNA breaks 
and complex chromosomal rearrangements that compromise cell 
viability (Scully et al., 1997a; Moynahan et al., 1999; Snouwaert 
et al., 1999). As such, BRCA1 knockout mice and mice carrying 
a BRCA1 deletion mutant (BRCA111/11) are embryonic lethal 
(Xu et al., 2001; Evers and Jonkers, 2006). Although lethality 
Loss of 53BP1 rescues BRCA1 deficiency and is as-sociated with BRCA1-deficient and triple-negative breast cancers (TNBC) and with resistance to geno-
toxic drugs. The mechanisms responsible for decreased 
53BP1 transcript and protein levels in tumors remain un-
known. Here, we demonstrate that BRCA1 loss activates 
cathepsin L (CTSL)–mediated degradation of 53BP1. Ac-
tivation of this pathway rescued homologous recombina-
tion repair and allowed BRCA1-deficient cells to bypass 
growth arrest. Importantly, depletion or inhibition of CTSL 
with vitamin D or specific inhibitors stabilized 53BP1 and 
increased genomic instability in response to radiation 
and poly(adenosine diphosphate–ribose) polymerase in-
hibitors, compromising proliferation. Analysis of human 
breast tumors identified nuclear CTSL as a positive bio-
marker for TNBC, which correlated inversely with 53BP1. 
Importantly, nuclear levels of CTSL, vitamin D receptor, 
and 53BP1 emerged as a novel triple biomarker signature 
for stratification of patients with BRCA1-mutated tumors 
and TNBC, with potential predictive value for drug re-
sponse. We identify here a novel pathway with prospec-
tive relevance for diagnosis and customization of breast 
cancer therapy.
BRCA1 loss activates cathepsin L–mediated 
degradation of 53BP1 in breast cancer cells
David A. Grotsky,1,2,3 Ignacio Gonzalez-Suarez,2,3 Anna Novell,4 Martin A. Neumann,1,2,3 Sree C. Yaddanapudi,2,3 
Monica Croke,1 Montserrat Martinez-Alonso,4 Abena B. Redwood,2,3 Sylvia Ortega-Martinez,2,3 Zhihui Feng,2,5 
Enrique Lerma,6,7 Teresa Ramon y Cajal,6,7 Junran Zhang,2,5 Xavier Matias-Guiu,4 Adriana Dusso,2,4  
and Susana Gonzalo1,2,3
1Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St. Louis, MO 63104
2Department of Radiation Oncology and 3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63108
4Department of Pathology, Molecular Genetics, and Nephrology, Hospital Universitario Arnau de Vilanova, Universidad de Lleida, Institute of Biomedical Research  
in Lleida, Lleida 25198, Spain
5Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH 44106
6Department of Pathology and 7Department of Medical Oncology, Hospital Santa Creu I Sant Pau, Barcelona 08025, Spain
© 2013 Grotsky et al. This article is distributed under the terms of an Attribution–Noncommercial–
Share Alike–No Mirror Sites license for the first six months after the publication date (see 
http://www.rupress.org/terms). After six months it is available under a Creative Commons 
License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at 
http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
IO
L
O
G
Y
 o
n
 April 13, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published January 21, 2013
http://jcb.rupress.org/content/suppl/2013/01/17/jcb.201204053.DC1.html 
Supplemental Material can be found at:
JCB • VOLUME 200 • NUMBER 2 • 2013 188
Accumulation of 53BP1 in this context promotes indiscriminate 
NHEJ and chromosomal instability that ultimately causes prolif-
eration arrest or cell death. Conversely, in cells double deficient 
in BRCA1 and 53BP1, end-resection is allowed, rescuing HR 
(Bunting et al., 2010). Consistent with this model, 53BP1 loss 
reduces the sensitivity of BRCA1-deficient cells to genotoxic 
agents such as cisplatin and mitomycin C (Bouwman et al., 
2010) and to poly(ADP-ribose) polymerase inhibitors (PARPi; 
Farmer et al., 2005; Bunting et al., 2010), compounds at the 
forefront for breast cancer therapy (Gartner et al., 2010). Thus, 
BRCA1-deficient cells are thought to down-regulate 53BP1 as 
a means to ensure proliferation/viability.
Up-regulation of 53BP1 levels represents a promising strat-
egy for treatment of breast tumors with the poorest prognosis and 
for improving their response to PARPi and other DNA-damaging 
strategies. However, we lack knowledge about how 53BP1 mRNA 
and protein levels are down-regulated in cancer cells. We previously 
identified a pathway regulating 53BP1 protein levels (Gonzalez- 
Suarez et al., 2011; Redwood et al., 2011a,b). Up-regulation of the 
cysteine protease cathepsin L (CTSL) leads to accumulation of the 
protease in the nucleus, degradation of 53BP1 protein, and defects 
in NHEJ. Importantly, inhibition of CTSL activity by treatment 
with vitamin D or specific inhibitors stabilizes 53BP1 protein 
levels and rescues NHEJ defects (Gonzalez-Suarez et al., 2011).
in BRCA111/11 mice can be rescued by abrogation of ATM, 
Chk2, or p53, these mice ultimately develop tumors and pre-
mature aging (Cao et al., 2006). Recently, loss of the DNA 
repair factor 53BP1 was shown to rescue embryonic lethality 
in BRCA1-deficient mice while maintaining a low incidence 
of tumorigenesis and normal aging (Cao et al., 2009). This is 
in contrast to 53BP1 knockout mice, which are cancer prone 
(Ward et al., 2003), suggesting that 53BP1 contributes to the 
developmental defects of BRCA1-deficient mice and that 53BP1 
loss has different consequences for cancer and aging in the con-
text of BRCA1 proficiency or deficiency.
Loss of 53BP1 promotes viability of BRCA1-deficient 
cells by rescuing HR function (Cao et al., 2009; Bouwman 
et al., 2010; Bunting et al., 2010). Importantly, down-regulation 
of 53BP1 was observed in human BRCA1-related breast cancer 
and TNBC and was suggested to allow these tumors to over-
come the genomic instability caused by HR defects (Bouwman 
et al., 2010). 53BP1 facilitates DNA DSB repair by nonho-
mologous end joining (NHEJ; Schultz et al., 2000; Fernandez- 
Capetillo et al., 2002; Wang et al., 2002; Xie et al., 2007) and 
also affects HR via inhibition of BRCA1-mediated DSB end-
resection (Bunting et al., 2010). The current model is that 
BRCA1 deficiency hinders end-resection of DSBs by CtIP and 
the Mre11–Rad50–Nbs1 complex, an essential event in HR. 
Figure 1. Bypass of growth arrest after BRCA1 loss 
is associated with CTSL up-regulation and 53BP1 deg-
radation. (A) MCF7 cells were lentivirally transduced 
with an shRNA for depletion of BRCA1 (shBRCA1) 
or a control shRNA scrambled (sh scr) and BRCA1 
levels were assessed by Western blot immediately 
after selection. (B) Proliferation rate shows that BRCA1 
depletion induces growth arrest. The mean ± SD of 
three independent experiments is shown (SD too 
small to show at some time points). (C) Western blots 
show 53BP1 and CTSL levels in growth-arrested cells. 
(D) Proliferation rate of BRCA1-deficient cells that over-
come growth arrest. The mean ± SD of three inde-
pendent experiments is shown (SD too small to show 
at some time points). (E) Western blots show levels 
of BRCA1, 53BP1, and CTSL in control and BOGA 
cells (representative experiment of 25 biological re-
peats). (F) Relative expression of BRCA1, CTSL, and 
53BP1 in control and BOGA cells as determined by 
qRT-PCR. The mean ± SD of three independent experi-
ments is shown. Asterisk shows p-value of statistical 
significance (*, P ≤ 0.05). NS, not statistically sig-
nificant differences. (G) Western blots show BRCA1 
and 53BP1 levels upon reconstitution of BRCA1 by 
transient transfection into BRCA1-deficient cell lines—
BOGA cells (left) and HCC1937 (right). An empty 
vector (EV) was used as control. -Tubulin was the 
loading control.
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for the depletion of 53BP1. The human breast cancer cell line 
MCF7, which is BRCA1 and 53BP1 proficient, was depleted 
of BRCA1 via lentiviral transduction with shRNAs (Fig. 1 A  
and Fig. S1 A). As previously shown in human fibroblasts 
(Tu et al., 2011), depletion of BRCA1 in MCF7 cells induces 
growth arrest (Fig. 1 B). BRCA1-deficient cells did not show differ-
ences in the levels of 53BP1 or CTSL proteins immediately after 
growth arrest (Fig. 1 C). Interestingly, after approximately two 
weeks in culture, BRCA1-deficient cells resumed proliferation, 
albeit at a slower rate than control cells (Fig. 1 D). Importantly, 
BRCA1-deficient cells that overcome growth arrest (herein 
referred to as BOGA cells, for clarity) exhibit increased CTSL 
and decreased 53BP1 protein levels (Fig. 1 E). This signature 
was also observed in MDA-MB-231 breast cancer cells that 
overcome the growth arrest induced by depletion of BRCA1 
(Fig. S1 B). Similar changes in CTSL and 53BP1 protein levels 
were observed with different shRNAs for depletion of BRCA1 
(Fig. S1 C). Monitoring transcripts levels by quantitative RT-PCR 
(qRT-PCR) revealed transcriptional up-regulation of CTSL in 
BOGA cells without significant changes in 53BP1 transcript 
levels, indicating a decrease in 53BP1 protein stability (Fig. 1 F). 
To confirm a role for BRCA1 in the regulation of 53BP1 levels, we 
reconstituted BRCA1 via transient transfection in BOGA cells 
Here, we demonstrate that BRCA1-deficient cells activate 
CTSL-mediated degradation of 53BP1 as a means to overcome 
genomic instability and growth arrest. In addition, depletion or 
inhibition of CTSL in these cells increases genomic instability 
in response to ionizing radiation (IR) or PARPi. Lastly, we iden-
tify high levels of nuclear CTSL and low levels of 53BP1 and 
vitamin D receptor (VDR) as a novel signature in subsets of 
breast cancer patients. We envision that the status of nuclear 
CTSL, VDR, and 53BP1 could be used for customization of 
breast cancer therapy.
Results
BRCA1-deficient cells activate CTSL-
mediated degradation of 53BP1  
to bypass growth arrest
Previous studies demonstrated that loss of 53BP1 rescues the 
BRCA1-deficient phenotype (Cao et al., 2009; Bouwman et al., 
2010; Bunting et al., 2010). We also showed that CTSL regulates 
the stability of 53BP1 (Gonzalez-Suarez et al., 2011; Redwood 
et al., 2011a,b). Here, we investigated whether breast tumor cells 
are able to down-regulate 53BP1 upon loss of BRCA1 to restore 
proliferation/viability and if CTSL is one of the factors responsible 
Figure 2. CTSL is responsible for the degra-
dation of 53BP1 that allows bypass of growth 
arrest in BOGA cells. (A) MCF7 cells were 
transduced with sh53BP1, shBRCA1, or both. 
After selection, BRCA1, 53BP1, and CTSL levels 
were monitored by Western blot. (B) Graphs 
compare proliferation rates between control 
cells and 53BP1/BRCA1-depleted cells (left) 
and between 53BP1/BRCA1-depleted cells 
and BRCA1-depleted cells (right). Depletion 
of 53BP1 prevents growth arrest upon BRCA1 
loss (representative experiment of three biologi-
cal repeats). (C) Control and BOGA cells were 
transduced with shCTSL or control shRNA (sh 
luc) and the levels of CTSL, BRCA1, and 53BP1 
were monitored by Western blot. Vertical lines 
show where gel pieces were juxtaposed. (D) Con-
trol or BOGA cells were treated with vitamin D 
(107 M) or vehicle (BGS) for 24 h and the 
levels of 53BP1 and p107, a known target of 
CTSL degradation, were monitored by West-
ern blot. (E) Control or BOGA cells were incu-
bated with the broad cathepsin inhibitor E-64 
(10 µM) or with vehicle (H2O) for 24 h, and 
the levels of 53BP1 and CTSL were monitored 
by Western blot. Note how cathepsin inhibi-
tion stabilizes 53BP1. (F) MCF7 cells growing 
asynchronously or growth arrested for 48 h 
by serum deprivation were analyzed for cell 
cycle profile (left) and for levels of CTSL, 53BP1, 
and BRCA1 by Western blot (right). Represen-
tative experiment of three biological repeats. 
Either Lamin A/C or -tubulin was used as 
loading control.
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of BRCA1 were not affected by depletion of CTSL (Fig. S2 B). 
Intriguingly, we observed a slight increase in BRCA1 protein in 
BOGA cells depleted of CTSL, suggesting a possible feedback 
mechanism of CTSL on BRCA1 protein levels, a notion that 
remains to be tested.
We previously demonstrated that vitamin D inhibits CTSL 
activity and stabilizes 53BP1 protein in mouse embryonic fibro-
blasts (MEFs; Gonzalez-Suarez et al., 2011). Here, we show that 
treatment of BOGA cells with vitamin D (1,25-dihydroxy-
vitamin D3) stabilized the levels of 53BP1 (Fig. 2 D). Similarly, 
treatment with the cathepsin inhibitor E-64 led to increased 
levels of 53BP1 protein (Fig. 2 E). These data demonstrate that 
cells growth arrested after BRCA1 loss activate CTSL-mediated 
degradation of 53BP1 to bypass the growth arrest imposed by 
BRCA1 deficiency. In addition, depletion or inhibition of CTSL 
can increase 53BP1 levels in the context of BRCA1 deficiency 
with potential therapeutic effects. Interestingly, growth arrest 
induced by serum deprivation in MCF7 cells also led to de-
creased levels of BRCA1, up-regulation of CTSL, and down-
regulation of 53BP1 (Fig. 2 F). These data suggest that BRCA1 
might regulate CTSL-mediated degradation of 53BP1 during 
the cell cycle and that the growth arrest induced by BRCA1 
depletion itself could contribute to the activation of CTSL-
mediated degradation of 53BP1.
CTSL-mediated degradation of  
53BP1 rescues HR defects in  
BRCA1-deficient cells
BRCA1 deficiency impairs DNA end-resection at DSBs and 
formation of RAD51-coated filaments that facilitate subse-
quent HR steps (Scully et al., 1997a,b; Moynahan et al., 1999; 
Snouwaert et al., 1999; Bhattacharyya et al., 2000; Sung et al., 
2003; Schlegel et al., 2006). Interestingly, loss of 53BP1 in 
BRCA1-deficient cells partially rescues HR and accumulation 
of RAD51 at IR-induced foci (IRIF; Bunting et al., 2010). Here, 
we determined how CTSL-mediated degradation of 53BP1 im-
pacts 53BP1 and RAD51 recruitment to DNA DSBs. We show 
that growth-arrested MCF7 cells immediately after BRCA1 
depletion retained their ability to recruit 53BP1 protein to 
IRIF (Fig. 3 A), which is consistent with normal 53BP1 levels. 
In contrast, BOGA cells were unable to form 53BP1 IRIF 
(Fig. 3 B), which is consistent with their decreased 53BP1 levels. 
Next, we determined if the deficiency in 53BP1 foci formation 
could be rescued by inhibiting CTSL. BOGA cells treated with 
vehicle were defective in the formation of 53BP1 IRIF, whereas 
treatment with vitamin D rescued 53BP1 IRIF (Fig. 3, C and D; 
and Fig. S3 A).
In contrast to 53BP1, RAD51 recruitment to IRIF was 
inhibited shortly after BRCA1 depletion in growth-arrested 
cells (Fig. S3 B). This defect was rescued in BOGA cells at 
1 h after IR (Fig. 4, A and B). The rescue was not because of 
an increase in BRCA1 levels, as BOGA cells were unable to 
form BRCA1-labeled IRIF (Fig. S3 C). We tested whether ac-
tivation of CTSL-mediated degradation of 53BP1 is behind the 
rescued recruitment of RAD51 to DSBs in BOGA cells. First, 
we show that stabilization of 53BP1 by vitamin D treatment 
reduced the extent of RAD51 IRIF (Fig. 4, A and B), revealing 
and the BRCA1-deficient breast cancer cell line HCC1937. 
Ectopic expression of BRCA1 resulted in stabilization of 
53BP1 in both cell lines (Fig. 1 G), revealing a novel function 
of BRCA1 in the stabilization of 53BP1 protein.
To determine if 53BP1 loss is responsible for the bypass 
of growth arrest in BRCA1-deficient cells, we depleted 53BP1 
before BRCA1 depletion. As shown in Fig. 2 A, we achieved a 
marked reduction of both 53BP1 and BRCA1 proteins. Impor-
tantly, previous depletion of 53BP1 prevented the characteristic 
growth arrest that follows BRCA1 depletion (Fig. 2 B). These 
data indicate that loss of 53BP1 allows BRCA1-deficient cells 
to bypass growth arrest. Interestingly, cells that were depleted 
of 53BP1 before depletion of BRCA1 also up-regulated CTSL 
(Fig. S2 A), suggesting that up-regulation of CTSL is indepen-
dent of 53BP1 status.
Next, we determined whether CTSL is responsible for 
the degradation of 53BP1 in BRCA1-deficient cells by depleting 
CTSL in control and BOGA cells (Fig. 2 C and Fig. S2 B). 
Depletion of CTSL stabilized 53BP1 protein levels in BOGA 
cells, mirroring those of control cells, whereas transcript levels 
Figure 3. Regulation of 53BP1 IRIF in BOGA cells by vitamin D. (A) Immuno-
fluorescence to detect 53BP1 IRIF in control (sh scr) and growth-arrested 
BRCA1-depleted cells (shBRCA1) 1 h after 8 Gy of IR. (B) The same assay 
was performed as in A but after bypass of growth arrest (BOGA cells). 
(C) Immunofluorescence performed in control and BOGA cells treated with 
vitamin D or vehicle 24 h before IR. Note how treatment with vitamin D 
restores 53BP1 IRIF in BOGA cells. (D) Graph shows the percentage of 
cells that form 53BP1 IRIF in the presence of vitamin D or vehicle. Cells 
with >10 53BP1 IRIF were considered positive. At least 1,000 cells were 
analyzed per condition in one experiment. Error bars were calculated 
using the exact binomial test. Asterisk shows p-value of statistical signifi-
cance (*, P ≤ 0.05). Bars, 10 µm.
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of 53BP1 hinders NHEJ in BRCA1-deficient cells. However, 
these cells are still able to repair DSBs although at a lower rate, 
suggesting that repair by HR or alternative NHEJ might remain 
relatively intact, which is consistent with RAD51 foci being able 
to form early after IR.
Cells deficient in HR become dependent on alternative path-
ways of DNA DSB repair, which often form complex chromo-
somal aberrations that trigger cell cycle arrest or death. Loss of 
53BP1 is sufficient to reduce the extent of aberrant chromosome 
structures in BRCA1-deficient cells (Bunting et al., 2010). Here, 
we determined whether stabilization of 53BP1 in BRCA1- 
deficient cells exacerbates the extent of genomic instability after 
IR by analyzing chromosomal aberrations in metaphase spreads. 
We did not find a profound increase in chromosome aberrations 
after IR in BOGA cells (Fig. 5 B), in agreement with the defi-
ciency in BRCA1 and 53BP1. However, stabilization of 53BP1 
in this context by vitamin D treatment significantly increased the 
percentage of metaphases with aberrant chromosomes after IR. 
Similarly, stabilization of 53BP1 in BOGA cells by treatment 
with the cathepsin inhibitor E-64 markedly increased genomic 
instability after IR (Fig. 5 C). Consistent with the increase in 
genomic instability, treatment of BOGA cells with vitamin D 
or E-64 significantly reduced their recovery from IR (Fig. 5, 
D and E). Thus, CTSL inhibition could represent a novel strategy 
to induce radiosensitivity in specific types of breast tumors.
To confirm that inhibition of CTSL-mediated degradation 
of 53BP1 is responsible for the increase in chromosomal aber-
rations after IR, we analyzed genomic instability in BOGA cells 
depleted of CTSL. These cells showed a marked increase in 
an unprecedented role for vitamin D in modulating HR. Similarly, 
depletion of CTSL reduced the ability of BOGA cells to re-
cruit RAD51 to DSBs (Fig. 4 C). Intriguingly, although con-
trol cells formed RAD51 IRIF for up to 6 h, the percentage of 
BOGA cells positive for RAD51 IRIF decreased significantly 
over time (Fig. 4 D and Fig. S4), indicating that 53BP1 defi-
ciency in BOGA cells does not completely compensate for the 
absence of BRCA1. These data demonstrate that by activating 
CTSL-mediated degradation of 53BP1, BRCA1-deficient cells 
can rescue to a certain extent the HR defects to promote sur-
vival and that this pathway can be disrupted by inhibiting CTSL 
activity. These findings provide a novel strategy to modulate 
HR efficiency in BRCA1-deficient cells.
Consequences of CTSL-mediated 
degradation of 53BP1 for DNA repair  
and genomic stability
To determine the functional consequences of CTSL-mediated 
degradation of 53BP1 in BRCA1-deficient cells, we evaluated 
the kinetics of DNA DSB repair by performing comet assays 
under neutral, nondenaturing conditions (Olive et al., 1990). 
Fig. 5 A shows that BOGA cells exhibited defects in the fast 
phase of repair corresponding to classical NHEJ (Iliakis et al., 
2004), which is consistent with our previous finding that up-
regulation of CTSL in MEFs leads to defects in the fast phase 
of repair through degradation of 53BP1 (Gonzalez-Suarez et al., 
2011). Furthermore, inhibition of CTSL with vitamin D res-
cued the kinetics of DNA DSB repair, mirroring control cells 
(Fig. 5 A). These results suggest that CTSL-mediated degradation 
Figure 4. Regulation of RAD51 IRIF in BOGA 
cells by CTSL and vitamin D. (A) Immunofluor-
escence to detect RAD51 IRIF after 8 Gy of 
IR in control and BOGA cells after treatment 
with vitamin D or vehicle. Plus denotes posi-
tive cells (>10 IRIF) and minus negative cells. 
(B) Graph shows the percentage of cells that 
form RAD51 IRIF 1 h after IR in the presence 
of vitamin D or vehicle. Approximately 1,000 
cells were analyzed per condition. Error bars 
were calculated using the exact binomial test. 
Asterisk shows p-value of statistical significance 
(*, P ≤ 0.05). (C) Quantitation of RAD51 IRIF 
in control or BOGA cells proficient or deficient 
in CTSL showing reduced number of positive 
cells in CTSL-depleted BOGA cells. At least 
200 cells were analyzed per condition. Error 
bars were calculated using the exact binomial 
test. Asterisk shows p-value of statistical sig-
nificance (*, P ≤ 0.05). (D) Quantitation of 
percentage of cells positive for RAD51 IRIF 
at different times after IR and upon treatment 
with vitamin D or vehicle. Note how BOGA 
cells exhibit defects in RAD51 IRIF 3 and 6 h 
after IR. Bar, 10 µm.
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genomic instability, in agreement with the resistance of cells 
double deficient in 53BP1 and BRCA1 to this treatment. Inter-
estingly, stabilization of 53BP1 by vitamin D increased the extent 
of chromosomal aberrations in response to PARPi, suggesting 
that inhibition of CTSL-mediated degradation of 53BP1 could 
induce sensitivity to PARPi.
Increased levels of nuclear CTSL in TNBC 
and tumors from patients with BRCA1 
germline mutations
Although CTSL is one of the most abundant proteases in the 
endosomal/lysosomal compartment, it has also been identified 
in the nucleus (Goulet et al., 2004; Duncan et al., 2008). We 
previously showed that up-regulation of CTSL leads to accumu-
lation of the protease in the nucleus and degradation of 53BP1 
(Gonzalez-Suarez et al., 2011). Recent studies demonstrated 
that loss of 53BP1 is more frequent in TNBC and BRCA1- 
mutated human breast cancer (Bouwman et al., 2010). Here, we 
determined whether up-regulation of CTSL occurs in human 
breast cancers and if it correlates with decreased levels of 
chromosomal aberrations after IR, when compared with cells 
deficient in either BRCA1 or CTSL alone (Fig. 6 A). Further-
more, we determined if the effect of vitamin D increasing 
genomic instability after IR in BOGA cells is mediated by 
53BP1 by monitoring chromosomal aberrations in cells doubly 
depleted of 53BP1 and BRCA1. In these cells, the combination 
of vitamin D and IR did not result in the profound increase in 
genomic instability (Fig. 6 B) that we observed in BOGA cells 
(Fig. 5 B). These results demonstrate that vitamin D exerts its 
effect in part by stabilizing 53BP1 levels and that the extent of 
CTSL-mediated degradation of 53BP1 is a key determinant of the 
ability of BRCA1-deficient cells to deal with the DNA damage 
generated by IR and putatively other genotoxic agents.
BRCA1-deficient cells are exquisitely sensitive to PARPi 
(Bryant et al., 2005; Drew et al., 2011). Importantly, loss of 
53BP1 reduces the sensitivity of these cells to PARPi (Bunting 
et al., 2010; Aly and Ganesan, 2011). We assessed whether 
stabilization of 53BP1 in BOGA cells would increase the extent 
of genomic instability induced by PARPi. As shown in Fig. 6 C, 
treatment of BOGA cells with PARPi did not result in profound 
Figure 5. Effect of CTSL inhibition on DNA repair 
and genomic stability in BOGA cells. (A) Neutral comet 
assays after 8 Gy of IR show higher olive moments, 
and thus defects in the fast phase of DNA repair in 
BOGA cells. Inhibition of CTSL activity by treatment 
with vitamin D (107 M) 24 h before IR rescues de-
fects in DNA DSB repair. (B) Control and BOGA cells 
were incubated with vehicle control (C) or vitamin D 
(VD) for 24 h before IR with 2 Gy (IR). Cells collected 
24 h after IR were analyzed for genomic instability 
by quantitating the percentage of metaphases present-
ing with chromosomal aberrations, as shown in the 
images. N, number of independent experiments (50 
metaphases analyzed per condition in each experi-
ment). (C) Control and BOGA cells were incubated 
with the cathepsin inhibitor (E-64) or vehicle control 
(C) for 24 h before IR, and the extent of genomic insta-
bility was assessed as in B. (D) Graph shows relative 
numbers of BOGA cells 4 d after treatment with IR, 
vitamin D, or a combination of both. Treatment protocol 
as in B. (E) Graph shows relative numbers of BOGA 
cells 4 d after treatment with IR, E-64, or a combina-
tion of both. Treatment performed as in C. All values 
expressed as mean ± SD. N, number of independent 
experiments. Asterisk denotes a p-value of statistical 
significance (*, P ≤ 0.05). Bars, 10 µm.
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Previous studies in human colon cancer cells showed a 
correlation between expression of VDR and cystatin D, an inhibi-
tor of several cathepsins including CTSL, and up-regulation of 
cystatin D by vitamin D (Alvarez-Díaz et al., 2009). In addition, 
our in vitro data show that vitamin D inhibits CTSL-mediated 
degradation of 53BP1. Vitamin D actions require a functional 
nuclear VDR (Dusso et al., 2005). Because VDR levels are 
reduced in several human cancers and BRCA1 loss causes de-
fective VDR translocation to the nucleus (Deng et al., 2009), we 
hypothesized that there might be a threshold for nuclear VDR 
that inhibits CTSL-mediated degradation of 53BP1. High levels 
of nuclear VDR could explain the signature of tumors with high 
53BP1. In addition, given the inhibitory effect of vitamin D on 
this pathway, we monitored the levels of VDR, which mediates 
most of vitamin D’s cellular effects. We performed immunohis-
tochemical analyses of multitumor tissue microarrays (TMAs) 
constructed with tissue from 249 patients with sporadic breast 
cancer (Fig. 7 and Table 1) classified into four molecular sub-
types: luminal A, luminal B, Her2, and triple negative.
Immunohistochemical scores (Hscores; ranging from 
0 to 300) for Ki67, ER, CTSL, 53BP1, and VDR provided 
a semi-quantitative measurement of their expression for each 
tumor subtype (Pallares et al., 2009). As shown in Fig. 7, stain-
ing of CTSL was both cytoplasmic and nuclear, whereas 53BP1 
staining was only nuclear. Table 1 summarizes the immunohis-
tochemistry results. Whereas cytoplasmic CTSL Hscores were 
similar in all tumor subtypes, nuclear CTSL Hscores were mark-
edly enhanced in triple-negative tumors. In agreement with the 
in vitro findings, these high nuclear CTSL Hscores concur with 
lower 53BP1 Hscores in TNBC compared with all other tumor 
types. Furthermore, using the median nuclear Hscores for CTSL 
and 53BP1 of 0 and 150, respectively, as cut-off points with 
identical statistical power, we confirmed statistically significant 
differences in CTSL and 53BP1 expression among molecular 
tumor types, with TNBC emerging as a remarkably different 
tumor subtype. Table 2 shows that 60% of triple-negative tumors 
elicited Hscores for nuclear CTSL >0, a frequency more than 
twofold higher than for any other molecular type (P = 0.0013). 
Also, 75% of triple-negative tumors expressed 53BP1 Hscores 
below 150 compared with 39–49% of all other tumor types 
(P = 0.0049), clearly showing that high expression of nuclear 
CTSL and low expression of 53BP1 is significantly more asso-
ciated with TNBC than any other molecular type. Thus, we 
identified nuclear CTSL as a novel biomarker for subsets of TNBC 
patients (Fig. S5). Importantly, this new signature (high nuclear 
CTSL and low 53BP1) could serve to stratify TNBC patients.
Next, we analyzed breast tumors from patients with 
germline mutations in BRCA1 (n = 18) or BRCA2 (n = 14) by 
immunohistochemistry (Tables 3 and 4). In comparison with 
sporadic TNBC, tumors from patients with BRCA1 germline 
mutations elicited the same high Hscores for nuclear CTSL 
(P = 0.95) and low Hscores for 53BP1 (P = 1). In contrast, 
tumors from patients with BRCA2 germline mutations had 
nuclear CTSL Hscores significantly lower than BRCA1- 
related tumors. Accordingly, 53BP1 Hscores were higher in 
tumors from patients with BRCA2 germline mutations than 
in BRCA1-related tumors or all molecular subtypes of spo-
radic tumors. These results support our in vitro data for a role 
of CTSL in the degradation of 53BP1 in BRCA1-deficient 
cells. Importantly, Fig. 8 A shows a statistically significant 
inverse linear correlation between Hscores for nuclear 53BP1 
and CTSL in all tumor subtypes with positive nuclear CTSL 
expression. However, a coefficient of determination of only 
6.6% indicates that 93.4% of the variability in 53BP1 Hscores 
cannot be accounted for by increases in nuclear CTSL. Thus, 
additional factors might contribute to CTSL-mediated deg-
radation of 53BP1 in these tumors. Identifying these factors 
could help to discriminate subsets of patients in which this 
pathway is activated.
Figure 6. Chromosomal aberrations in response to IR and PARPi.  
(A) BOGA cells transduced with an shRNA control (sh scr) or an shRNA for 
CTSL were irradiated with 2 Gy and the percentage of cells with aberrant 
metaphases was quantified 24 h after IR. A total of 400 metaphases were 
analyzed in one experiment (50 per condition). (B) MCF7 cells depleted of 
53BP1 and BRCA1 (sh53BP1 + shBRCA1) were treated with vitamin D or 
vehicle 24 h before IR, and the percentage of metaphases with aberrant 
chromosomes was quantitated. A total of 800 metaphases were analyzed 
in one experiment (100 per condition). (C) BOGA cells were treated with 
vitamin D (107 M) 24 h before treatment with the PARPi EB-47 (Pi, 1.2 µg/ml) 
for an additional 48 h. Graph shows the percentage of metaphases with 
chromosomal aberrations. Images show the types of chromosomal aberra-
tions observed. A total of 400 metaphases were analyzed in one experi-
ment (100 per condition). Bar, 10 µm.
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patients with TNBC (in which BRCA1 is frequently somati-
cally altered) and tumors from patients with BRCA1 germline 
mutations (Tables 2 and 4). Based on our in vitro data, these 
signatures could potentially be used as predictors of the re-
sponse of specific tumors to radiation, cross-linking reagents, 
and PARPi.
Discussion
Breast cancers classified as triple negative or BRCA1 defi-
cient are among the most aggressive and difficult to treat. These 
tumors harbor similar DNA repair deficiencies and gene expres-
sion profiles (Foulkes et al., 2010). Of particular relevance is the 
loss of BRCA1 function and decrease in 53BP1 levels, two fac-
tors with a decisive role in the choice of DNA DSB repair 
mechanisms: HR or NHEJ (Bouwman et al., 2010). Recent 
landmark studies demonstrated that loss of 53BP1 allows sur-
vival of BRCA1-deficient cells and induces their resistance 
to DNA-damaging therapeutic strategies (Cao et al., 2009; 
Bothmer et al., 2010; Bouwman et al., 2010; Bunting et al., 
2010). Thus, stabilization of 53BP1 levels represents a promis-
ing new strategy for the treatment of these cancers. However, 
before this study, no information was available about how the 
levels of 53BP1 mRNA and/or protein are down-regulated in 
breast tumor cells.
This study demonstrates that up-regulation of CTSL is a 
mechanism responsible for lowering 53BP1 protein levels in 
BRCA1-deficient cells, allowing bypass of the characteristic 
Hscores for both nuclear CTSL and 53BP1. Our hypothesis is 
supported by the findings of a direct linear correlation between 
nuclear levels of VDR and 53BP1 for all 249 tumor types (Pearson 
correlation r = 0.238; P = 0.0002). By analyzing the linear rela-
tionship for those tumors with nuclear VDR expression below 
the median Hscore of 120 obtained in the 249 sporadic tumors 
(Fig. 8 B), we found an increase in the slope of the linear regres-
sion of nuclear 53BP1 and CTSL Hscores as well as increased 
coefficient of determination (from 6.6 to 29.2%). Furthermore, 
when the correlation between 53BP1 and CTSL was examined 
exclusively in TNBC, the nonsignificant correlation depicted in 
Fig. 8 C becomes significant when only tumors with nuclear 
VDR <120 are examined (P < 0.0027), as seen in Fig. 8 D, with 
a coefficient of determination of 80.2%. Indeed, the outliers in 
Fig. 8 C correspond to patients with VDR Hscores far above 
120, which maintain high Hscores for nuclear 53BP1 despite 
high Hscores for nuclear CTSL (Fig. 8 E, top). The bottom 
panels of Fig. 8 E show the most common biomarker signature 
found in TNBC and BRCA1-related tumors. Furthermore, mean 
nuclear Hscores for VDR are lower in tumors from patients with 
BRCA1 mutations compared with TNBC (Tables 1 and 3), sug-
gesting that loss of BRCA1 may also impair VDR translocation 
to the nucleus. The VDR Hscores in BRCA2 germline muta-
tions depicted in Table 3 suggest that only BRCA1 mutations 
impact VDR translocation to the nucleus, resulting in less inhi-
bition of CTSL-mediated degradation of 53BP1.
In summary, this study reveals a new triple biomarker sig-
nature—nuclear VDR, CTSL, and 53BP1—for stratification of 
Figure 7. A new signature for subsets of TNBC patients. Immuno-
histochemical analysis was performed in breast tumor TMAs from 
249 patients, which included four molecular subtypes: luminal A, 
luminal B, Her2, and triple negative. Representative images of 
immunohistochemical labeling with Ki67, ER, Her2, CTSL, and 
53BP1 are shown. Note that although cytoplasmic CTSL is observed 
in all tumor subtypes, nuclear CTSL is markedly up-regulated in 
a subset of TNBC. In addition, TNBC tumors exhibit a marked 
decrease in 53BP1. Bars, 100 µm.
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et al., 2005; Gocheva and Joyce, 2007). Thus, inhibition of CTSL 
activity could represent a strategy for cancer treatment (Lankelma 
et al., 2010). Our previous studies in MEFs revealed novel roles 
for CTSL in the degradation of nuclear factors with functions 
in cell cycle regulation (Rb family members) and DNA repair 
(53BP1; Gonzalez-Suarez et al., 2011). The present study shows 
that CTSL is up-regulated in breast cancer cells after BRCA1 
depletion and that increased CTSL activity impacts mechanisms 
growth arrest upon loss of BRCA1 function (Fig. 9). It is possible 
that other mechanisms such as degradation of 53BP1 by the pro-
teasome also contribute to 53BP1 reduction in BRCA1-deficient 
tumor cells. In addition, previous studies showed that subsets 
of BRCA1-mutated tumors also exhibit reduced 53BP1 mRNA 
levels (Bouwman et al., 2010), indicating that different mecha-
nisms can be activated in BRCA1-deficient cells to lower 53BP1 
levels and ensure survival. Importantly, depletion of CTSL or 
inhibition of its activity stabilizes 53BP1 protein levels and in-
duces genomic instability in BRCA1-deficient cells after IR or 
treatment with PARPi.
Furthermore, we show a significant negative correlation 
between 53BP1 and nuclear CTSL in human tumors. The high-
est median levels of nuclear CTSL concur with the lowest levels 
of 53BP1 in a subset of TNBC and tumors from patients with 
BRCA1 germline mutations and with low nuclear VDR levels. 
This study has revealed a new pathway, activated upon loss of 
BRCA1 function, which is anticipated to contribute to the pro-
gression of breast cancers with the poorest prognoses. Inhibition 
of this pathway by treatment with vitamin D or cathepsin inhibi-
tors could provide a new therapeutic strategy for breast cancer. 
Importantly, the status of the pathway offers great potential 
as a predictive biomarker for response to therapy.
CTSL up-regulation after growth arrest by 
BRCA1 loss and serum deprivation
In a variety of cancers, up-regulation of CTSL has been asso-
ciated with increased invasiveness, metastasis, and overall de-
gree of malignancy (Jedeszko and Sloane, 2004; Skrzydlewska 
Table 2. Frequency of CTSL, 53BP1, and VDR expression within 
molecular subtype relative to the median values in sporadic human 
breast cancer
Proteins Molecular type n (%) Fisher exact test 
p-value
Nuclear CTSL >0 Luminal A 23 (23.2) 0.0013
 Luminal B 22 (31.9)
 Erbb2 (1) 12 (27.3)
 Triple negative (1) 21 (60.0)
53BP1 <150 Luminal A 59 (59.6) 0.0049
 Luminal B 35 (50.7)
 Erbb2 (4) 21 (51.2)
 Triple negative 9 (25.0)
Nuclear VDR <120 Luminal A 46 (48.4) 0.34
 Luminal B 40 (61.5)
Erbb2 (4) 25 (58.1)
 Triple negative 16(48.5)
Values denote the absolute (n) and the relative (%) frequencies of tumors with 
Hscore values above (nuclear CTSL) or below (nuclear 53BP1 and VDR) the me-
dian Hscore values for each protein in the overall population of sporadic breast 
cancer. Bolded frequency values highlight the molecular subtype responsible 
for the statistically significant difference identified with the Fisher exact test that 
compares all molecular types (bold p-value if significant difference).
Table 1. Immunohistochemical analysis of CTSL, 53BP1, and VDR expression in sporadic human breast cancer
Proteins Molecular type H score Kruskal-Wallis test  
p-value
 Mean (SD) Median [P25, P75] Min–Max
Cytoplasmic CTSL Luminal A 137 (36.6) 135 [110,160] 50–205 0.50
 Luminal B 134 (35.2) 130 [110,155] 75–-230
 Erbb2 (1) 141 (43.1) 135 [110,171] 50–230
 Triple negative (1) 145 (35.2) 140 [120,175] 80–200
Nuclear CTSL Luminal A 8 (18.0) 0 [0, 0] 0–90 <0.0001
 Luminal B 8 (14.9) 0 [0, 15] 0–75
 Erbb2 (1) 9 (18.3) 0 [0, 5] 0–75
 Triple negative (1) 42 (44.3) 30 [0, 83] 0–125
53BP1 Luminal A 155 (56.5) 160 [120, 200] 0–270 0.0002
 Luminal B 150 (45.8) 150 [120, 170] 40–280
 Erbb2 (4) 154 (58.1) 150 [110, 200] 20–300
 Triple negative 112 (44.4) 105 [80, 143] 0–190
Cytoplasmic VDR Luminal A (4) 50 (50.9) 50 [0, 90] 0–185 0.22
 Luminal B (4) 52 (50.8) 50 [0, 80] 0–190
 Erbb2 (2) 53 (48.8) 50 [0, 95] 0–160
 Triple negative (3) 69 (50.6) 50 [20, 110] 0–170
Nuclear VDR Luminal A (4) 121 (68.2) 110 [100, 170] 0–300 0.78
 Luminal B (4) 125 (65.2) 130 [90, 160] 0–300
 Erbb2 (2) 122 (73.3) 125 [95, 160] 0–300
 Triple negative (3) 114 (62.3) 110 [80, 150] 0–270
Values are mean and median Hscores for nuclear and cytoplasmic CTSL, 53BP1, and VDR per tumor type. Min–Max denotes minimal and maximal values within the 
tumor subtype. Dispersion is assessed by SD and percentiles 25 and 75 ([P25, P75]); (X) represents X missing values per molecular type as a result of insufficient 
specimen. Bolded Hscore values highlight the molecular subtype responsible for the statistically significant difference identified with the Kruskal-Wallis test that com-
pares all molecular types (bold p-value if significant difference).
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mRNAs. Those BRCA1-deficient cells that are able to activate 
CTSL-mediated degradation of 53BP1 would be poised to con-
tinue proliferation.
Furthermore, we show that cells growth arrested in G0/G1 
by serum deprivation also exhibit low BRCA1, high CTSL, and 
low 53BP1 levels, suggesting a functional relationship between 
these proteins during the cell cycle. We envision a model where 
the decrease in BRCA1 levels in G0/G1 phases contributes to 
CTSL-mediated degradation of 53BP1. Up-regulation of CTSL 
could also trigger a feedback mechanism that lowers BRCA1 
protein levels. This is supported by studies showing that BRCA1 
is a target for degradation by cysteine proteases of the cathep-
sin family, although the specific cathepsin was not identified 
of DNA DSB repair. Several lines of evidence implicate BRCA1 
in transcriptional regulation, chromatin remodeling (Bochar 
et al., 2000; Mullan et al., 2006), and maintenance of heterochro-
matin silencing (Zhu et al., 2011). Epigenetic mechanisms such as 
DNA methylation and expression of miRNAs have been linked 
to BRCA1 function (Shukla et al., 2010; Kawai and Amano, 2012; 
Tanic et al., 2012). Although the mechanism by which BRCA1- 
deficient cells activate CTSL remains unknown, the latency in 
the activation of this pathway indicates that CTSL is not a direct 
transcriptional target of BRCA1. Rather, we speculate that the 
loss of BRCA1 might result in alterations in chromatin structure 
that either make the CTSL gene more permissive to transcrip-
tional activation over time and/or alter the stability of CTSL 
Table 3. Immunohistochemical analysis of CTSL, 53BP1, and VDR expression in tumors from patients with BRCA1 or BRCA2 germline mutations
Proteins Mutation type H score M-W test  
p-value  
(vs. sporadics)
M-W test  
p-value  
(BRCA1 vs. BRCA2)
Mean (SD) Median  
[P25, P75]
Min–Max
Cytoplasmic CTSL BRCA1 mutation (4) 119 (34.2) 110  
[100, 138]
60–190 0.0563 0.88
BRCA2 mutation (1) 118 (46.2) 120  
[100, 120]
100–150 0.0437
Nuclear CTSL BRCA1 mutation (4) 38 (45.2) 30  
[15, 45]
0–180 0.0001 0.0494
BRCA2 mutation (1) 15 (22.7) 4  
[0, 15]
0–75 0.19
53BP1 BRCA1 mutation (1) 111 (28.4) 115  
[100, 125]
70–175 0.0016 0.0001
BRCA2 mutation (1) 198 (43.6) 210  
[185, 220]
110–270 0.0008
Cytoplasmic VDR BRCA1 mutation 86 (38.5) 100  
[50, 100]
0–150 0.0048 0.0011
BRCA2 mutation (3) 145 (36.7) 150  
[115, 165]
100–200 <0.0001
Nuclear VDR BRCA1 mutation 66 (52.9) 53  
[27, 100]
0–180 0.0010 0.0001
BRCA2 mutation (3) 175 (57.8) 170  
[135, 193]
110–300 0.0074
Values are mean and median Hscores for nuclear and cytoplasmic CTSL, 53BP1, and VDR in BRCA1- or BRCA2-related tumors. Min–Max denotes minimal and 
maximal values within the tumor. Dispersion is assessed by SD and percentiles ([P25, P75]); (X) represents X missing values. Bolded p-values highlight the statistical 
significance of differences measured by Mann-Whitney test (M-W) between each tumor mutation subtype versus the overall population of sporadic breast cancer or 
between tumors with BRCA1 versus BRCA2 germline mutations.
Table 4. Frequency of CTSL, 53BP1, and VDR expression within BRCA1- and BRCA2-related tumors
Proteins Mutation type n (%) Fisher exact test  
p-value  
(vs. sporadics)
Fisher exact test  
p-value  
(BRCA1 vs. BRCA2)
Nuclear CTSL >0 BRCA1 mutation (4) 12 (85.7) 0.0001 0.10
 BRCA2 mutation (1) 7 (53.8) 0.13
53BP1 <150 BRCA1 mutation (1) 2 (11.8) 0.0019 0.0001
 BRCA2 mutation (1) 11 (84.6) 0.0210
Nuclear VDR <120 BRCA1 mutation (1) 3 (16.7) 0.0027 0.0051
 BRCA2 mutation (1) 8 (72.7) 0.35
Values denote the absolute (n) and the relative (%) frequencies of BRCA1- or BRCA2-related tumors with Hscore values above (nuclear CTSL) or below (nuclear 
53BP1 and VDR) the median Hscore values for each protein in sporadic breast tumors. Bolded p-values highlight the statistically significant difference measured 
by Fisher exact test comparing a molecular subtype with either the overall population of sporadic breast cancer or between tumors with BRCA1 versus BRCA2 
germline mutations.
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a lesser effect in cells with normal CTSL expression. This is 
likely because up-regulation of CTSL leads to an increase in the 
levels of nuclear CTSL, which is low relative to other cellular 
compartments in normal cells (Gonzalez-Suarez et al., 2011). 
Although our attempts to localize nuclear CTSL in MCF7 
BOGA cells by Western blot were unsuccessful, the immuno-
histochemical analysis of TMA clearly showed that a subset of 
TNBC and BRCA1-deficient tumors present with high levels of 
nuclear CTSL. Interestingly, these tumors are often also defi-
cient in nuclear VDR and 53BP1.
The ability to impact the choice of DNA DSB repair path-
way could have profound consequences for cancer therapy. In 
tumor cells that activate CTSL-mediated degradation of 53BP1 
as a means to ensure survival, cathepsin inhibition could stabi-
lize 53BP1, increase genomic instability, and induce growth 
(Blagosklonny et al., 1999). Future studies need to determine 
if CTSL functions as a regulator of 53BP1 and BRCA1 protein 
stability during the cell cycle.
Vitamin D and cathepsin inhibitors can 
modulate DNA DSB repair choice
Our previous study in MEFs (Gonzalez-Suarez et al., 2011) 
and the present study in human breast cancer cells reveal an 
unprecedented role for vitamin D and cathepsin inhibitors in 
the regulation of DNA DSB repair choice. By stabilizing 53BP1 
protein levels in the context of BRCA1 deficiency, CTSL in-
hibitors facilitate repair of DSBs by NHEJ while inhibiting 
HR. Importantly, our data indicate that both vitamin D and 
cathepsin inhibitors impact 53BP1 stability, especially in cells 
that up-regulate CTSL, i.e., BRCA1-deficient cells, showing 
Figure 8. Nuclear 53BP1 expression corre-
lates inversely with nuclear CTSL expression 
in sporadic human breast cancer. (A–D) Linear 
regression analysis between Hscores for nu-
clear 53BP1 and CTSL in sporadic breast cancer 
samples with Hscores for nuclear CTSL >0. 
Note the high variability in nuclear 53BP1 
Hscores in tumors without nuclear CTSL. The 
linear regression analysis of the association 
between nuclear 53BP1 and CTSL depicted 
in A (linear regression coefficient r= 0.42; 
P = 0.02; coefficient of determination r2 = 
6.6%) and B (r = 0.93; P = 0.0025; r2 = 
29.2%) include Hscores from both TNBC and 
no TNBC tumors, whereas C (r = 0.255; 
P = 0.294; r2 = 5.8) and D (r = 0.89; 
P = 0.0027; r2 = 80.2%) depict TNBC only. 
Note the marked increase in percentage of 
the variability in nuclear 53BP1 levels that 
can be explained by changes in nuclear CTSL 
parameters of B and D when only tumors with 
nuclear VDR Hscores <120 are included in 
the regression analysis. (E) Images of immuno-
histochemical analysis results in TNBC pa-
tients. Two different signatures were observed 
in these patients (as well as in patients with 
BRCA1 germline mutations). Top panels show 
the signature of a few TNBC patients: high 
nuclear CTSL, 53BP1, and VDR. Bottom pan-
els show the most common signature in TNBC 
patients: high nuclear CTSL, low 53BP1, and 
low nuclear VDR. Bars, 100 µm.
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showed a role for VDR in the up-regulation of cathepsin inhibitors 
(Alvarez-Díaz et al., 2009). Thus, it is tempting to speculate that 
vitamin D interventions could lead to VDR-induced expression 
of cystatins and the attenuation of CTSL-mediated degradation 
of 53BP1. Future studies testing this hypothesis might lead to 
new strategies of targeted therapy.
The combination of low nuclear VDR or high nuclear 
CTSL with low 53BP1 levels offers great potential for the strati-
fication of BRCA1-deficient and TNBC patients into different 
subgroups and as a predictive biomarker for the response of 
these patients to current therapies. In particular, the use of PARPi 
as single agents or in combination with radiation or chemother-
apy is a leading strategy for breast cancer management, espe-
cially for HR-deficient tumors (Farmer et al., 2005; Helleday 
et al., 2005; Fong et al., 2009; Tutt et al., 2010; Drew et al., 
2011). However, a significant fraction of these cancers acquire 
resistance to PARPi. A recent study in cell culture and mouse 
models demonstrated that loss of 53BP1 reduces the sensitivity 
of BRCA1-deficient cells to PARPi (Bunting et al., 2010).
Our study suggests that BRCA1-deficient and TNBC 
patients that exhibit low nuclear VDR, high nuclear CTSL, and 
low 53BP1 levels are likely to be proficient in HR and resistant 
to PARPi. Therefore, these patients will not benefit from this 
specific treatment unless levels of 53BP1 are stabilized. For 
these patients, treatment with vitamin D or CTSL inhibitors to 
stabilize 53BP1 levels in combination with PARPi might result 
in the most effective therapy.
Materials and methods
Cells maintained in DMEM, 10% FBS, and antibiotics/antimycotics were 
transduced with shRNAs and selected in media containing 0.5 mg/ml Geneti-
cin G418 or 2 µg/ml puromycin. Except for one shBRCA1 (5-TCAGTA-
CAATTAGGTGGGCTT-3) that was constructed by J. Zhang, the rest were 
purchased from the Genome Institute at Washington University (shBRCA 
sequences: 1, 5-GAGAATCCTAGAGATACTGAA-3; 2, 5-TATAGCTGTT-
GGAAGGACTAG-3; 3, 5-CCCTAAGTTTACTTCTCTAAA-3; 4, 5-GCC-
CACCTAATTGTACTGAAT-3; 5, 5-CCCACCTAATTGTACTGAATT-3).
Lentiviral transductions were performed as previously described 
(Gonzalez-Suarez et al., 2009). In brief, 293T cells were transfected with 
viral packaging (pHR’8.2R) and envelope (pCMV-VSV-G) plasmids along 
with the vector containing the shRNA of interest. After 48 h, viral media 
was collected and used to infect target cells in one 4–6-h infection. 
Cells were allowed to recover for 48 h and treated with the appropriate 
selection drug. Viral packaging and envelope plasmids were gifts from 
S. Stewart (Washington University, St. Louis, MO). HCC1937 cells were 
a gift from J. Zhang (Washington University, St. Louis, MO). HA-BRCA1 
(Addgene) transient transfections were performed using the X-tremeGENE 
HP transfection reagent (Roche). For growth arrest by serum deprivation, 
MCF7 cells were incubated in DMEM, 0.1% FBS, and antibiotics/antimy-
cotics for 48 h. DNA content was monitored after ethanol fixation and 
propidium iodide labeling (1 mg/ml in water).
Cell treatments
Vitamin D. Cells were incubated with 107 M 1,25-dihydroxyvitamin D3 
(Sigma-Aldrich) for 24–48 h, as indicated. Aliquots of 1 nmol 1,25- 
dihydroxyvitamin D3 were resuspended in 1 ml BGS and diluted in DMEM 
to a final concentration of 10% BGS. BGS was the vehicle control.
E-64. Cells were incubated with the broad-spectrum cathepsin inhibitor 
E-64 (Sigma-Aldrich) diluted in water at a concentration of 10 µM for 24 h.
PARPi. Cells were treated with the PARPi EB-47 (Sigma-Aldrich) 
diluted in water at a concentration of 1.2 µg/ml for 48 h.
IR. For determining the extent of genomic instability, cells were irra-
diated with 2 Gy and analysis of metaphase spreads was performed 24 h 
arrest and/or cell death, especially in combination with IR or 
PARPi. Thus, treatment with vitamin D or CTSL inhibitors could 
represent a new therapeutic strategy for specific types of breast 
tumors, if they can be identified.
Nuclear levels of CTSL, 53BP1, and VDR: 
a new predictive biomarker signature for 
drug response?
The analysis of TMA indicates that levels of nuclear CTSL rep-
resent a new positive biomarker for subsets of tumors having 
abnormalities in BRCA1, including TNBC (currently defined 
solely by the absence of Her2/neu, estrogen and progesterone 
receptors, and frequently showing somatic alterations of BRCA1 
function), and tumors arising in association with germline 
mutations in BRCA1. Similarly, we find that nuclear VDR levels 
correlate linearly with 53BP1 content in all tumor subtypes, and 
the lowest nuclear VDR levels correspond to TNBC and tumors 
from patients with BRCA1 germline mutations. The finding of 
the strong negative correlation between reductions in nuclear 
53BP1 with increases in nuclear CTSL levels (80% coefficient 
of determination) in TNBC with nuclear VDR <120 is very 
interesting, as TNBC is associated with severe vitamin D defi-
ciency (Peppone et al., 2011). Furthermore, a previous study 
Figure 9. Activation of CTSL-mediated degradation of 53BP1 allows 
BRCA1-deficient cells to overcome genomic instability and growth arrest. 
Depletion of BRCA1 in breast cancer cells leads to defects in HR, genomic 
instability, and growth arrest. Over time, BRCA1-deficient cells activate 
CTSL-mediated degradation of 53BP1, which rescues HR defects while 
inhibiting NHEJ. This allows BRCA1-deficient cells to overcome growth ar-
rest. Inhibition of CTSL activity via treatment with vitamin D or specific 
inhibitors stabilizes 53BP1 protein levels and induces genomic instability 
in response to IR and PARPi. Furthermore, up-regulation of CTSL-mediated 
degradation of 53BP1 could be regulated by nuclear VDR.
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Reagents (Applied Biosystems). BRCA1, 53BP1, CTSL, and 18S expression 
was determined using TaqMan Gene Expression Assays (Hs01556193_m1, 
Hs00996818_m1, Hs00377632_m1, and Hs99999901_s1; Applied 
Biosystems). All the reactions were performed in triplicate and the target 
gene and endogenous controls were amplified in the same plate. Relative 
quantitative measurements of target genes were determined by comparing 
the cycle thresholds.
Analysis of aberrant chromosomes
Cells were treated with vitamin D or E-64 for 24 h, irradiated, and al-
lowed to recover for 24 h. Cells treated with PARPi were pretreated with 
vitamin D for 24 h followed by combined treatment with vitamin D and 
PARPi for 48 h. After all treatments, cells were arrested in mitosis by treat-
ment with colcemid for 4 h and metaphase spreads were prepared by 
hypotonic swelling in 0.56% KCl, followed by fixation in 3:1 methanol/
acetic acid. Cell suspensions were dropped onto slides and stained for 
25 min in Wright-Giemsa Stain (Ricca Chemical Company) and then 
washed in water. Slides were allowed to dry and were mounted using 
Eukitt Mounting Reagent (Sigma-Aldrich) and analyzed at room tempera-
ture on a DM5000 B microscope using a 100× oil objective (NA 1.30). 
Images were acquired with the DFC350 FX digital camera using the 
Application Suite.
TMAs
A total of 249 tissue samples from patients with sporadic breast car-
cinoma were obtained at Hospital Universitari Arnau de Vilanova in 
Lleida, Lleida, Spain, from 1998 to 2012. An informed consent was ob-
tained from each patient and the study was approved by the local Ethi-
cal Committee. The series of 249 tumor samples included formalin-fixed, 
paraffin-embedded blocks for all patients, 165 core biopsies, before the 
initiation of neoadjuvant treatment, and 84 surgical specimens, before 
the initiation of adjuvant treatment. Tumors were classified according 
to the expression of proteins Ki67, Er, and Her2 into four molecular 
subtypes: luminal A (n = 99), luminal B (n = 69), Her2 (n = 45), and 
triple negative (n = 36). Luminal A tumors are steroid hormone receptor 
positive, are negative for Her2, contain less than 30% of Ki67 positive 
cells, and tend to have a good prognosis. Luminal B tumors are steroid 
hormone receptor–positive, negative for Her2, contain more than 30% 
Ki67-positive cells, and tend to have a worse prognosis than luminal A. 
In contrast, Her2 tumors are positive for Her2 and have been shown to 
have a poor prognosis. Triple-negative tumors are negative for steroid 
hormone receptors and Her2 and have the worst prognosis. Moreover, 
tissue samples were also obtained from 18 breast cancers from patients 
carrying a BRCA1 germline mutation (luminal A, n = 1; luminal B, n = 1; 
Her2, n = 2; triple negative, n = 15), and from 14 breast cancers from pa-
tients carrying a BRCA2 germ-line mutation (luminal A, n = 6; luminal B, 
n = 2; Her2, n = 3; triple negative, n = 3). These patients had been 
treated in Hospital Santa Creu I Sant Pau, Barcelona, Spain.
We used a tissue arrayer device (Beecher Instrument) to construct the 
TMAs. Representative areas of all samples were marked in the correspond-
ing paraffin blocks. In each sample, we selected two cylinders (0.6 mm 
of largest diameter) for the immunohistochemical analysis.
Immunohistochemical analysis
TMA blocks were sectioned at a thickness of 3 µm, dried for 1 h at 65°C 
before being dewaxed in xylene and rehydrated through descending con-
centrations of ethanol, and washed with PBS. Ki67, ER, and Her2 were 
used to determine molecular subtype. Comparative studies of CTSL, VDR, 
and 53BP1 expression were performed on sequential serial sections. Anti-
gen retrieval for CTSL and ER was achieved by heat treatment at 95°C for 
20 min in a high pH solution (Dako). Heat-induced antigen retrieval for 
53BP1 and Ki67 was performed in a low pH solution (Dako). Before stain-
ing the sections, endogenous peroxidase was blocked. Primary antibodies 
and incubation times were as follows: CTSL (1:50; Santa Cruz Biotechnol-
ogy, Inc.; incubation overnight at 4°C); 53BP1 (1:2,500; Novus Biologi-
cals; incubation 20 min at room temperature); VDR (1:2,000; Abcam; 
incubation 20 min at room temperature); Ki67 (Ready-to-use; Dako; incu-
bation 20 min at room temperature); ER (Ready-to-use; Dako; incubation 
20 min at room temperature), and Her2 (Herceptest kit; Dako). The reac-
tion was visualized with the Streptovidin-Biotin Complex (Dako) for CTSL 
and Envision Flex (Dako) for 53BP1, Ki67, and ER. Sections were coun-
terstained with hematoxylin. Appropriate positive and negative controls 
were also tested.
Hscores provide a semiquantitative measurement of protein expres-
sion per tumor by taking into consideration the percentage of positive 
after IR. For assaying formation of IRIF, cells were irradiated with 8 Gy and 
fixed and processed for immunofluorescence 1, 3, or 6 h after IR as indi-
cated. For comet assays, cells were irradiated with 8 Gy.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, and 0.5% SDS) supplemented 
with PMSF, protease inhibitors (Sigma-Aldrich), and 20 mM DTT. Protein 
detection was performed using the following antibodies: BRCA1 (Santa 
Cruz Biotechnology, Inc.), 53BP1 (Novus Biologicals), CTSL (Santa Cruz 
Biotechnology, Inc.), -Tubulin (Sigma-Aldrich), and p107 (Santa Cruz 
Biotechnology, Inc.).
Immunofluorescence
For immunofluorescence of RAD51 and 53BP1, cells were plated on coverslips 
and fixed in 3.7% formaldehyde and 0.2% Triton-X 100 in PBS for 10 min 
at room temperature. Coverslips were washed and blocked for 1 h at 37°C 
in 1% BSA and 0.1% Triton X-100 in PBS. Incubation with antibodies recog-
nizing RAD51 (1:200; Santa Cruz Biotechnology, Inc.) or 53BP1 (1:1,000; 
Novus Biologicals) was performed for 1 h at 37°C, followed by washing in 
PBS and incubation with Alexa Fluor 488 goat anti–rabbit (1:1,000; Invitro-
gen) secondary antibody for 1 h at 37°C. After washing in PBS, coverslips 
were mounted using Vectashield with DAPI (Vector Laboratories).
BRCA1 immunofluorescence was performed following a protocol 
from the Fernandez-Capetillo laboratory (Centro Nacional de Investiga-
ciones Oncológicas, Madrid, Spain). In brief, cells were washed twice 
with PBS and incubated in CSK I buffer (10 mM Pipes, pH 6.8, 100 mM 
NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, and 0.5% Triton 
X-100) for 5 min. Coverslips were washed five times with cold PBS and 
fixed in modified STF buffer (150 mM 2-Bromo-2-nitro-1,3-propanediol, 
108 mM diazolidinyl urea, 10 mM sodium citrate, and 50 nM EDTA, pH 5.7) 
for 30 min at room temperature. Coverslips were then washed twice with 
cold PBS and permeabilized (PB buffer: 100 mM Tris-HCl, pH 7.4, 50 mM 
EDTA, pH 8.0, and 0.5% Triton X-100) for 15 min at room temperature 
followed by two washes in PBS. Blocking, antibody staining, and mount-
ing were performed as previously described with BRCA1 antibody (Santa 
Cruz Biotechnology, Inc.) diluted at 1:200 and Alexa Fluor 594 goat anti–
mouse secondary antibody (Invitrogen) diluted at 1:1,000.
Microscopy and photo capture was performed at room temperature 
on either an Eclipse 90i microscope (Nikon) using 60 or 100× oil objec-
tive lenses (NA 1.4 and 1.45, respectively) with a CoolSNAP ES2 digital 
camera (Photometrics) and MetaMorph (Version 7.1.2.0) or a DM5000 B 
microscope (Leica) using 63 or 100× oil objective lenses (NA 1.4 and 1.3, 
respectively) with a DFC350FX digital camera (Leica) and the Application 
Suite (Version 4.1.0; Leica).
Comet assay
Neutral comet assays were performed using CometSlide assay kits (Trevi-
gen). Treated cells were irradiated with 8 Gy and incubated at 37°C for dif-
ferent periods of time to allow DNA to repair (0, 30, 60, and 90 min). Cells 
were embedded in agarose, lysed, and subjected to neutral gel electropho-
resis. Cells were stained with ethidium bromide and visualized using a fluor-
escence microscope. Olive comet moments were calculated by multiplying 
the percentage of DNA in the tail by displacement between the means of the 
head and tail distributions as described previously (Olive et al., 1990). The 
program CometScore Version 1.5 (TriTek) was used to calculate olive mo-
ments. A total of 30 comets were analyzed per sample in each experiment.
Proliferation assay
To quantify growth upon depletion of BRCA1, cells were plated in tripli-
cate at 150,000 cells/well and counted 96 h later. Cell proliferation was 
measured in each cell line four times within a 14-d period. To quantify the 
growth of the sh53BP1/shBRCA1 cells, 4 × 106 cells were plated in 15-cm 
dishes and counted every 96 h for 20 d. To extrapolate proliferation to the 
respective time periods, we used the equation N = N0ekt where N is the final 
number of cells, N0 is the starting number of cells, k is ln2/DT (doubling 
time), and t is time in days (Sherley et al., 1995). For each 96-h period we 
calculated the doubling time and used it to estimate the number of cells (N) 
that would result from initially plating 150,000 (N0) and cultured them for 
a given period of time. The doubling times for the control cells remained 
constant throughout the time period, whereas the doubling times for the 
shBRCA1 cells started increasing once the cells overcame the growth arrest.
qRT-PCR
RNA was isolated using the RNAqueous-4PCR kit (Ambion). cDNA was 
generated from 500 ng of total RNA using TaqMan Reverse Transcription 
 o
n
 April 13, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published January 21, 2013
JCB • VOLUME 200 • NUMBER 2 • 2013 200
and X. Matias-Guiu contributed to the writing of the manuscript. S.C. 
Yaddanapudi, M. Croke, A.B. Redwood, and S. Ortega-Martinez contributed 
to some of the experiments. Z. Feng and J. Zhang provided essential reagents 
such as the shRNA specific for depletion of BRCA1 and HCC1937 trans-
fected with BRCA1, as well as helpful discussions and advice. A. Novell, 
M. Martinez-Alonso., X. Matias-Guiu, and A. Dusso performed all the analysis 
of human TMA. E. Lerma and T. Ramon y Cajal provided breast tumor samples 
from patients with BRCA1/2 germline mutations. A. Dusso provided seminal 
advice and helpful discussions throughout the progression of the project, and 
her expertise in vitamin D biology and analysis of human tumors was instru-
mental for the study. S. Gonzalo supervised the research and the preparation 
of the manuscript.
Submitted: 10 April 2012
Accepted: 13 December 2012
References
Alvarez-Díaz, S., N. Valle, J.M. García, C. Peña, J.M. Freije, V. Quesada, A. 
Astudillo, F. Bonilla, C. López-Otín, and A. Muñoz. 2009. Cystatin D 
is a candidate tumor suppressor gene induced by vitamin D in human 
colon cancer cells. J. Clin. Invest. 119:2343–2358. http://dx.doi.org/ 
10.1172/JCI37205
Aly, A., and S. Ganesan. 2011. BRCA1, PARP, and 53BP1: conditional synthetic 
lethality and synthetic viability. J. Mol. Cell Biol. 3:66–74. http://dx.doi 
.org/10.1093/jmcb/mjq055
Bhattacharyya, A., U.S. Ear, B.H. Koller, R.R. Weichselbaum, and D.K. Bishop. 
2000. The breast cancer susceptibility gene BRCA1 is required for sub-
nuclear assembly of Rad51 and survival following treatment with the 
DNA cross-linking agent cisplatin. J. Biol. Chem. 275:23899–23903. 
http://dx.doi.org/10.1074/jbc.C000276200
Blagosklonny, M.V., W.G. An, G. Melillo, P. Nguyen, J.B. Trepel, and L.M. 
Neckers. 1999. Regulation of BRCA1 by protein degradation. Oncogene. 
18:6460–6468. http://dx.doi.org/10.1038/sj.onc.1203068
Bochar, D.A., L. Wang, H. Beniya, A. Kinev, Y. Xue, W.S. Lane, W. Wang, F. 
Kashanchi, and R. Shiekhattar. 2000. BRCA1 is associated with a human 
SWI/SNF-related complex: linking chromatin remodeling to breast cancer. 
Cell. 102:257–265. http://dx.doi.org/10.1016/S0092-8674(00)00030-1
Bothmer, A., D.F. Robbiani, N. Feldhahn, A. Gazumyan, A. Nussenzweig, 
and M.C. Nussenzweig. 2010. 53BP1 regulates DNA resection and 
the choice between classical and alternative end joining during class 
switch recombination. J. Exp. Med. 207:855–865. http://dx.doi.org/10 
.1084/jem.20100244
Bouwman, P., A. Aly, J.M. Escandell, M. Pieterse, J. Bartkova, H. van der 
Gulden, S. Hiddingh, M. Thanasoula, A. Kulkarni, Q. Yang, et al. 2010. 
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative 
and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17:688–695. 
http://dx.doi.org/10.1038/nsmb.1831
Bryant, H.E., N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. 
Kyle, M. Meuth, N.J. Curtin, and T. Helleday. 2005. Specific killing of 
BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) poly-
merase. Nature. 434:913–917. http://dx.doi.org/10.1038/nature03443
Bunting, S.F., E. Callén, N. Wong, H.T. Chen, F. Polato, A. Gunn, A. Bothmer, 
N. Feldhahn, O. Fernandez-Capetillo, L. Cao, et al. 2010. 53BP1 
inhibits homologous recombination in Brca1-deficient cells by block-
ing resection of DNA breaks. Cell. 141:243–254. http://dx.doi.org/ 
10.1016/j.cell.2010.03.012
Cao, L., S. Kim, C. Xiao, R.H. Wang, X. Coumoul, X. Wang, W.M. Li, X.L. Xu, 
J.A. De Soto, H. Takai, et al. 2006. ATM-Chk2-p53 activation prevents 
tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. 
EMBO J. 25:2167–2177. http://dx.doi.org/10.1038/sj.emboj.7601115
Cao, L., X. Xu, S.F. Bunting, J. Liu, R.H. Wang, L.L. Cao, J.J. Wu, T.N. 
Peng, J. Chen, A. Nussenzweig, et al. 2009. A selective requirement 
for 53BP1 in the biological response to genomic instability induced 
by Brca1 deficiency. Mol. Cell. 35:534–541. http://dx.doi.org/10.1016/ 
j.molcel.2009.06.037
Deng, C., E. Ueda, K.E. Chen, C. Bula, A.W. Norman, R.A. Luben, and A.M. 
Walker. 2009. Prolactin blocks nuclear translocation of VDR by regulat-
ing its interaction with BRCA1 in osteosarcoma cells. Mol. Endocrinol. 
23:226–236. http://dx.doi.org/10.1210/me.2008-0075
Drew, Y., E.A. Mulligan, W.T. Vong, H.D. Thomas, S. Kahn, S. Kyle, A. 
Mukhopadhyay, G. Los, Z. Hostomsky, E.R. Plummer, et al. 2011. 
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 
in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. 
Cancer Inst. 103:334–346. http://dx.doi.org/10.1093/jnci/djq509
cells and the intensity of their staining. An Hscore ranging from 0 
(no immune reaction) to 300 (maximal immunoreactivity) was obtained with 
the formula Hscore = 1× (% light staining) + 2× (% moderate staining) 
+ 3× (% strong staining). The reliability of such scores for the interpretation 
of immunohistochemical staining in TMAs has been reported previously 
(Pallares et al., 2009).
Her2 staining was evaluated according to a standard protocol (Hercep-
Test; Dako) and scored as four intensities (i.e., negative = 0; weak = 1+; 
moderate = 2+; and strong = 3+), considering negative Her2 expression 
for intensity values of 0, 1+, and 2+ when there was no amplification 
by FISH and positive for intensity values of 3+ and 2+, when 2+ was 
amplified by FISH. For each marker, there were a variable number of non-
assessable cases caused by technical problems including no representa-
tive tumor sample left in the cylinders, detachment, cylinders missed while 
constructing the array, necrosis, and absence of viable tumor cells in the 
TMA sections.
Statistical analysis
For the in vitro experiments, a two-tailed student’s t test was used to calculate 
statistical significance of the observed differences. Excel 2010 (Microsoft) 
was used for the calculations. In all cases, differences were considered sta-
tistically significant when P < 0.05. For some figures the 95% confidence in-
terval based on an exact binomial distribution was calculated to determine 
significant differences among samples. For the TMA studies, a Kruskal-Wallis 
test was used to test the statistical significance of the observed differences in 
CTSL, VDR, and 53BP1 Hscores between molecular breast tumor subtypes. 
Tumors were partitioned according to cut-off nuclear Hscores for CTSL, 
53BP1, and VDR selected by their median values as >0, <150, and <120, 
respectively. Once cut-off points were applied, Fisher exact test was used to 
assess the statistical significance of the differences in the distribution of the 
two categories of CTSL, 53BP1, and VDR Hscores above or below cut-off 
points for all breast tumor types. In the analysis of BRCA1 and BRCA2 sam-
ples, we used the Mann-Whitney test to analyze Hscore differences between 
them as well as differences of each of them with the sample of sporadic tu-
mors, and we used the Fisher exact test to assess differences in the distribu-
tions of groups defined by the same cut-off points used for the sporadic 
tumors. The subsample of TNBC was also compared with the sample of ger-
minal BRCA1 mutated cancers using the same statistical tests. The Pearson 
correlation coefficient together with linear regression models assessed the 
statistical significance of the relationship between nuclear CTSL and 53BP1 
Hscores. R package was used to perform all TMA statistical tests. Differences 
were considered significant when P < 0.05.
Online supplemental material
Fig. S1 shows an entire BRCA1 Western blot as well as Western blots 
of activation of CTSL-mediated degradation of 53BP1 in MDA-MB-231 
cells and by different BRCA1 shRNAs. Fig. S2 shows qRT-PCR results for 
the sh53BP1/shBRCA1 and the shBRCA1/shCTSL doubly depleted cells. 
Fig. S3 shows results from immunofluorescence studies of 53BP1, BRCA1, 
and RAD51 IRIF in the generated cell lines and upon different treatments. 
Fig. S4 shows RAD51 foci formation data at 3 and 6 h after IR. Fig. S5 
shows differences in CTSL levels among different molecular subtypes of 
breast cancer. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201204053/DC1.
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